The initiation of coverage by Morgan Stanley with an Equal-Weight rating suggests a neutral outlook on the stock, indicating that the stock is adequately valued at its current price. The raised price target to $383 implies a positive view on the stock's potential to grow, but since the rating is not an upgrade, the short-term impact on the stock price may be moderate. Investors may view the new price target as a sign of confidence in the company's prospects, which could have a positive but limited effect on the stock price.